Apple, Samsung DRAM Deal; Csop HK-Korea Tech+ ETF (03431.HK) -2.24%
- As of 9:48 on November 19, Csop Ftse Hk-Korea Tech+ Index Etf (03431.HK) fell 2.24% intraday to HK$7.840, with turnover of HK$2,292,201.
- The ETF tracks the FTSE HK-Korea Tech+ Index, covering 20 Hong Kong and 20 Korean technology stocks, with assets under management of HK$909 million.
- Samsung Electronics and Apple are finalising a four-to-five-year DRAM supply deal starting in the first half of 2027; SK hynix has signed a similar agreement.
NewTimeSpace News: As of 9:48 on November 19, 2026, Csop Ftse Hk-Korea Tech+ Index Etf (03431.HK) fell 2.24% intraday to a latest price of HK$7.840, with a turnover of HK$2,292,201, a trading volume of 292,000 shares, and a turnover rate of 0.26%. Its current net asset value per unit is HK$8.0423, and its assets under management stand at HK$909 million.
NewTimeSpace understands that Csop Ftse Hk-Korea Tech+ Index Etf (03431.HK) is managed by CSOP Asset Management Limited, with the full name CSOP FTSE HK-Korea Tech+ Index ETF, and an investment objective of providing investment results that closely track the FTSE ETF Connect HK-Korea Tech+ Index (Net Total Return), before fees and expenses. The ETF primarily adopts a physical representative sampling strategy, investing 50% to 100% of net asset value in Index securities, and may invest up to 100% of net asset value directly in equities listed on the Stock Exchange of Hong Kong and the Korea Exchange; where the manager considers it beneficial, it uses a synthetic representative sampling strategy as a supplement, investing up to 50% of net asset value in financial derivative instruments such as funded total return swaps, with any constituent's deviation from Index weightings not exceeding 3%; it may also engage in securities lending of up to 50% of net asset value (expected around 20%). The Index is constructed under the HKEX ETF Connect framework and covers Hong Kong-listed technology stocks eligible for Stock Connect together with leading Korean technology stocks; by market capitalisation it selects up to 20 technology securities listed on the Stock Exchange of Hong Kong and 20 listed on the Korea Exchange, for 40 constituents in total, weighted by free-float adjusted market capitalisation. The caps on Hong Kong and Korean stocks are 65% and 35% respectively, individual constituent caps are 10% and 15%, and the Index is reviewed semi-annually. As of November 18, the ETF had assets under management of HK$909 million and a net asset value per unit of HK$8.0423.
On the news front, Samsung Electronics and Apple are finalising a long-term DRAM supply agreement, according to Maeil Business News Korea on November 18. The deal is expected to take effect in the first half of 2027 and run for four to five years, setting a minimum supply volume while leaving final pricing to future market conditions. Apple is the only major technology company yet to sign a long-term DRAM deal with Samsung, making the shift unusual; it has also signed a similar agreement with SK hynix on terms more favourable to the supplier. Samsung Electronics and SK hynix are both major constituents of the FTSE HK-Korea Tech+ Index.
KB Securities believes it would be an overinterpretation to equate a slowdown in US AI investment directly with weaker global memory demand, as China's independent AI infrastructure investment can act as a buffer: China accounts for about 29% of global memory demand, and its relative weight would rise if US demand share falls. The bottleneck in AI data-centre investment has spread from GPUs to memory, networking and power, with HBM expansion potentially crowding out conventional DRAM capacity. US regulation is more likely to take a conditional form than to broadly curb AI investment, so near-term volatility does not change the direction of demand.
- Insurer Dividend Demand; Fubon HS High Dividend ETF (03190.HK) -0.17%
- Anthropic Lists on Nasdaq; CSOP HK-US Tech ETF (03442.HK) -0.93%
- ABBISKO-B (02256.HK): Presents CDK4 Inhibitor ABSK192 Data at ENA
- HUTCHMED (00013.HK): Presents HMPL-A830 Preclinical Data at ENA
- HBM HOLDINGS-B (02142.HK): AI Drug LET003 Gets IND Nod in China